这项工作由国家卫生研究院NIGMS 056062资助。

没有什么可透露的。

这种基因-环境相互作用研究的设计使我们能够获得关于5-LOX同位素在硝基质通路中的双重性质的新信息。通过执行HPLC测量盐水或MPTP治疗后，缺乏5-LOX异丙胺及其野生类型的垃圾伴侣的转基因药物的纹状单胺，我们能够注意到，其缺乏似乎在有毒条件下是保护性的（图1），但在正常情况下，缺乏酶会降低纹状多巴胺水平，并可能有害。因此，我们能够证明，5-LOX同位素有助于纹状多巴?...

使用基因-环境相互作用模型提供了一种方法，模仿可能影响特发性帕金森病（PD）的危险因素，并提供了一个机会来辨别机械学的见解，不太可能通过单独使用遗传或毒性系统来阐明1，2。在这里，我们说明了这一点，并描述了应用1-甲基-4-苯-1，2，3，6-四氢皮里丁（MPTP）小鼠模型的硝基质变性3，以更好地了解脂氧酶（LOX）异酶活性的神经发炎和毒性4的选择性。虽然LOX同位素的作用已被广泛评估在外周疾病5，6以及CNS疾病，包括中风7和阿尔茨海默病8，9，同位素家族的作用，在硝基质功能和退化相关的PD是不太清楚的，值得研究。MPTP神经毒素表现出乳胶病原体通路的优先退化，并重新概括了纹状多巴胺耗竭和尼格勒多巴胺细胞损失，这是PD患者10运动损伤的基础。虽然这种模型没有复制非运动和运动PD行为和坦率的α-核素阳性Lewy身体病理学的全干部， 它一直有助于阐明新的机械靶点，有助于尼古斯特菌损伤和早期转化测试，因为它是最好的特征非侵入性模型，可用于可靠地产生硝基细胞死亡伴随着纹状多巴胺损失11-15。广泛使用MPTP小鼠，其范式从急性，亚急性到慢性16-18，已允许标准化的给药，导致轻度至重度硝基层损伤19，20与激活不同的毒性机制，这取决于治疗方案18，21，22。因此，这允许一个"病变窗口"的目标，可能会导致增强或减少硝基质损伤取决于治疗剂或转基因模型使用23-25。
对于转化和发现生物学研究来说，同样必要的是用于评估损伤的技术以及这些方法提供的证据。对于 MPTP 鼠标模型， 评估病变的既定指标是测量纹状多巴胺语气的标记物，包括HPLC的多巴胺及其代谢物，以及西方斑点分析酪氨酸羟基酶（TH），多巴胺合成中的限速酶，以及利用西式污点分析和免疫化学4的胶质活化等退行事件指标。虽然这些是经典的神经化学、生化和组织学程序，但这些技术提供了关于黑鬼多巴明神经通路内损伤程度的关键和可重复读数，表明毒性机制，并被证明是了解PD退行性事件的宝贵工具。

<table border="0" cellpadding="0" cellspacing="0" width="1227">
	<tbody>
		<tr height="20">
			<td height="20" style="height:20px;width:481px;">1-Methyl-4-phenyl-1,2,3,6-tetra-hydropyridine hydrochloride (MPTP-HCL)</td>
			<td style="width:211px;">Sigma-Aldrich</td>
			<td style="width:121px;">M0896</td>
			<td style="width:351px;">for PD modeling</td>
			<td style="width:64px;"></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">4% Formaldehyde (paraformaldehyde) solution, phosphate-buffered (PFA)</td>
			<td>American MasterTech Scientific</td>
			<td>BUP0157</td>
			<td>for immersion fixation</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Perchloric acid ACS reagent, 70% (PCA)</td>
			<td>Sigma-Aldrich</td>
			<td>244252</td>
			<td>for HPLC acid extraction</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Tris Base</td>
			<td>Sigma-Aldrich</td>
			<td>T1503</td>
			<td>for tissue homogenization</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Ethylenediaminotetraacetic acid disodium salt dihydrate (EDTA)</td>
			<td>Sigma-Aldrich</td>
			<td>E1644</td>
			<td>for tissue homogenization</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Protease inhibitor cocktail</td>
			<td>Sigma-Aldrich</td>
			<td>P8340</td>
			<td>for tissue homogenization</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Phosphatase inhibitor cocktail</td>
			<td>Sigma-Aldrich</td>
			<td>P5726</td>
			<td>for tissue homogenization</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Sodium Hydroxide (NaOH)</td>
			<td>Sigma-Aldrich</td>
			<td>S5881</td>
			<td>for Lowry protein assay</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Sucrose, molecular biology, &#8805;99.5% (GC)&#160;</td>
			<td>Sigma-Aldrich</td>
			<td>S0389</td>
			<td>for cryoprotection</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Phosphate buffered saline, powder, pH 7.4 (for 0.01 M PBS)</td>
			<td>Sigma-Aldrich</td>
			<td>P3813</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">BCA Protein Assay Kit</td>
			<td>Pierce/Thermo</td>
			<td>23225</td>
			<td>for protein determination</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Novex 12% Tris-Glycine Mini Gels 1.0 mm, 12-well</td>
			<td>Invitrogen/Life Technologies</td>
			<td>EC60052BOX</td>
			<td>for SDS-PAGE</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">NuPAGE LDS Sample Buffer (4x)</td>
			<td>Invitrogen/Life Technologies</td>
			<td>NP0007</td>
			<td>for SDS-PAGE</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Novex Sharp Prestained Protein Standard&#160;</td>
			<td>Invitrogen/Life Technologies</td>
			<td>LC5800</td>
			<td>protein ladder</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Glycine</td>
			<td>Sigma-Aldrich</td>
			<td>G7126</td>
			<td>for SDS-PAGE</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Sodium dodecyl sulfate, electrophoresis, 98.5% (SDS)</td>
			<td>Sigma-Aldrich</td>
			<td>L3771</td>
			<td>for SDS-PAGE</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Methyl Alcohol, Anhydrous, Reagent&#160;</td>
			<td>American MasterTech Scientific</td>
			<td>SPM1057C</td>
			<td>methanol for transfer</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Sodium chloride (NaCl), ACS reagent</td>
			<td>Sigma-Aldrich</td>
			<td>S9888</td>
			<td>saline and buffers</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Nonfat dry milk powder</td>
			<td>Carnation</td>
			<td>n/a</td>
			<td>for immunoblotting</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Ponceau S solution in 5% acetic acid&#160;</td>
			<td>Sigma-Aldrich</td>
			<td>P7170</td>
			<td>for immunoblotting</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Anti-Tyrosine Hydroxylase (TH), sheep polyclonal</td>
			<td>Chemicon/Millipore</td>
			<td>AB1542</td>
			<td>for immunofluorescence&#160;</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Anti-Tyrosine Hydroxylase (TH), rabbit polyclonal</td>
			<td>Pel-Freez Biologicals</td>
			<td>P40101-0</td>
			<td>for immunoblotting</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Anti-&#946; Actin, rabbit</td>
			<td>Sigma-Aldrich</td>
			<td>A2066</td>
			<td>for immunoblotting</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Anti-Glial Fibrillary Acidic Protein (GFAP), rabbit polyclonal</td>
			<td>Chemicon/Millipore</td>
			<td>AB5804</td>
			<td>for immunofluorescence</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Anti-Glial Fibrillary Acidic Protein (GFAP), mouse monoclonal</td>
			<td>Covance Inc.</td>
			<td>SMI-22R</td>
			<td>for immunoblotting</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Tween-20</td>
			<td>Sigma-Aldrich</td>
			<td>P1379</td>
			<td>for immunoblotting</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Goat Anti-Rabbit IgG (H+L), Peroxidase Conjugated&#160;</td>
			<td>Fisher Scientific</td>
			<td>31462</td>
			<td>for immunofluorescence</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">goat anti-sheep, peroxidase conjugated</td>
			<td>Pierce/Thermo</td>
			<td>31480</td>
			<td>for immunofluorescence</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">goat anti-mouse, peroxidase conjugated</td>
			<td>Pierce/Thermo</td>
			<td>31430</td>
			<td>for immunofluorescence</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">SuperSignal West Pico Chemiluminescent Substrate</td>
			<td>Pierce/Thermo</td>
			<td>34078</td>
			<td>for immunoblotting</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">CL-XPosure Film 7 in x 9.5 in&#160;</td>
			<td>Pierce/Thermo</td>
			<td>34089</td>
			<td>for immunoblotting</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Restore Western Blot Stripping Buffer&#160;</td>
			<td>Pierce/Thermo</td>
			<td>21059</td>
			<td>for immunoblotting</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Citric acid monohydrate, ACS reagent, &#8805;99.0%&#160;</td>
			<td>Sigma-Aldrich</td>
			<td>C1909</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Normal Donkey Serum</td>
			<td>Millipore</td>
			<td>S30-100ML</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Polyvinylpyrrolidone (PVP)</td>
			<td>Sigma-Aldrich</td>
			<td>P5288</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Bovine Serum Albumin (BSA), lyophilized</td>
			<td>Sigma-Aldrich</td>
			<td>A3294</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Triton X-100</td>
			<td>Fisher Scientific</td>
			<td>BP151-01</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="19">
			<td height="19" style="height:19px;">Donkey anti-Rabbit IgG, Alexa Fluor 568-labeled&#160;</td>
			<td>Invitrogen/Life Technologies</td>
			<td>A10042</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Donkey Anti-Sheep IgG (H+L), FITC&#160;</td>
			<td>Jackson ImmunoResearch</td>
			<td>713-095-147</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">VECTASHIELD Hard-Set Mounting Medium with DAPI</td>
			<td>Vector Laboratories</td>
			<td>H-1500</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Normal Goat Serum</td>
			<td>Millipore</td>
			<td>S26-100ML</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">VECTASTAIN ABC Kit (Rabbit IgG )&#160;</td>
			<td>Vector Laboratories</td>
			<td>PK-4001</td>
			<td>for IHC; 10 &#181;l each of solutions A and B per 1 ml PBS (per instructions )</td>
		</tr>
		<tr height="24">
			<td height="24" style="height:24px;">DAB Peroxidase Substrate Kit, 3,3&#8217;-diaminobenzidine</td>
			<td>Vector Laboratories</td>
			<td>SK-4100</td>
			<td>for IHC; per 5 ml cold ddH2O, add 2 drops buffer stock solution, 2 drops DAB, and 1 drop H2O2 (H2O2 is added immediately before use)</td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Hydrogen peroxide, 30%</td>
			<td>Sigma-Aldrich</td>
			<td>216763</td>
			<td>for quench step in IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Rabbit anti-Iba1</td>
			<td>Biocare Medicals</td>
			<td>CP290A</td>
			<td>for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;width:481px;">Cresyl Violet Solution, Regular Strength&#160;</td>
			<td>FD Neurotechnologies</td>
			<td>PS102-01&#160;</td>
			<td>counterstain for Iba1 IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">95% Ethanol, reagent alcohol</td>
			<td>Sigma-Aldrich</td>
			<td>R8382</td>
			<td>dehydration for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">100% Absolute ethanol</td>
			<td>Mallinckrodt&#160;</td>
			<td>7019-10</td>
			<td>dehydration for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Acetic acid</td>
			<td>Sigma-Aldrich</td>
			<td>A6283</td>
			<td>destaining for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Xylene</td>
			<td>Sigma-Aldrich</td>
			<td>534056</td>
			<td>clearing agent for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">DPX Mountant</td>
			<td>Sigma-Aldrich</td>
			<td>06522</td>
			<td>mounting medium for DAB IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">O.C.T. Compound - Frozen Section Embedding Medium&#160;</td>
			<td>American MasterTech Scientific</td>
			<td>EMOCTCS</td>
			<td>embeddium medium for cryostat cutting</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Potassium permanganate</td>
			<td>Sigma-Aldrich</td>
			<td>223468</td>
			<td>to decontaminate DAB solution</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Dopamine hydrochloride</td>
			<td>Sigma-Aldrich</td>
			<td>H8502</td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">3,4-Dihydroxyphenylacetic acid (DOPAC)</td>
			<td>Sigma-Aldrich</td>
			<td>850217</td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Homovanillic acid (HVA)</td>
			<td>Sigma-Aldrich</td>
			<td>H1252</td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Perchloric acid (PCA) - 70%</td>
			<td>Sigma-Aldrich</td>
			<td>244252</td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Sodium dihydrogen phosphate monohydrate</td>
			<td>Sigma-Aldrich</td>
			<td>71504</td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Citric acid monohydrate</td>
			<td>Sigma-Aldrich</td>
			<td>C1909</td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">1-Octanesulfonic acid sodium salt (OSA)</td>
			<td>Sigma-Aldrich</td>
			<td>O8380</td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">EDTA</td>
			<td>Sigma-Aldrich</td>
			<td>E1644</td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Acetonitrile</td>
			<td>EMD</td>
			<td>AX0145-1</td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">HPLC-grade distilled deionized water (ddH2O)</td>
			<td>Millipore</td>
			<td></td>
			<td>for HPLC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">0.22 &#181;m GSTF membrane</td>
			<td>Millipore</td>
			<td></td>
			<td>for filtration</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Corning Netwells</td>
			<td>Sigma-Aldrich</td>
			<td>CLS3477</td>
			<td>polystyrene insert with polyester mesh bottom, for IHC</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;"></td>
			<td></td>
			<td></td>
			<td>[header]</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Ultrasonic cell disrupter (Soniprep 150)</td>
			<td>MSE</td>
			<td>MSE.41371.274</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Microcentrifuge</td>
			<td>Eppendorf</td>
			<td>5414R</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">ESA MD-150 reverse-phase column&#160;</td>
			<td>ESA</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">HPLC Pump (Ultimate 3000)</td>
			<td>Dionex</td>
			<td>ISO-3100BM</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">HPLC Autosampler (Ultimate 3000)</td>
			<td>Dionex</td>
			<td>WPS-3000TSL</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Electrochemical detector</td>
			<td>ESA</td>
			<td>Coulochem III</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Guard Cell</td>
			<td>ESA</td>
			<td>5020</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Analytical Cell</td>
			<td>ESA</td>
			<td>5011A</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Chromeleon software</td>
			<td>Dionex</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Eclipse E400</td>
			<td>Nikon</td>
			<td>E400</td>
			<td>light/fluorescent microscope</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Disposable mouse cage</td>
			<td>Ancare</td>
			<td>N10HT</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">Microfilter top</td>
			<td>Ancare</td>
			<td>N10MBT</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;"></td>
			<td></td>
			<td></td>
			<td>[header]</td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">5-LOX- deficient mice</td>
			<td>The Jackson Laboratory</td>
			<td>004155</td>
			<td></td>
			<td></td>
		</tr>
		<tr height="20">
			<td height="20" style="height:20px;">12/15-LOX-deficient mice</td>
			<td>The Jackson Laboratory</td>
			<td>002778</td>
			<td></td>
			<td></td>
		</tr>
	</tbody>
</table>

gene-environment interaction models to unmask susceptibility mechanisms in parkinson's disease

脂氧酶 （LOX） 活动与神经退行性疾病（如阿尔茨海默氏症）有关，但其对帕金森病 （PD） 发病机理的影响鲜为人知。基因-环境相互作用模型在揭开特定细胞通路毒性的影响方面有用，单凭遗传或毒性疾病模型是无法观察到的。要评估是否不同的LOX异位体有选择地有助于PD相关的神经退化，转基因（即 5-LOX和12/15-LOX缺乏）小鼠可以挑战一种毒素，模仿细胞损伤和死亡的紊乱。在这里，我们描述了使用神经毒素，1-甲基-4-苯-1，2，3，6-四氢胆碱（MPTP），它产生一个尼古斯特里亚病变，阐明LOX异位体对与PD相关的神经退化的独特贡献。在小鼠和非人类灵长类动物中使用MPTP是重新概括PD中硝基体损伤的既定证据。MPTP 诱发病变的程度通过 HPLC 对多巴胺及其代谢物的分析以及对酪氨酸羟基酶 （TH） 纹状体的半定量西方污点分析来衡量，该纹状体是多巴胺合成的限速酶。为了评估炎症标记，这可能证明LOX异酶选择性敏感性，胶质纤维酸性蛋白（GFAP）和Iba-1免疫组织化学在含有亚坦蒂亚尼格拉的大脑部分进行，GFAP西斑分析在纹状同源物上进行。这种实验方法可以为基因-环境相互作用提供新的见解，这些相互作用是尼古菌变性和PD的基础。

这种毒素暴露模式可在MPTP与盐水注射动物中产生显著且可检测到的20%纹状多巴胺耗竭。需要注意的是，不同数量的MPTP可能会产生轻微的或多或少的病变:因此，为了提高精度，建议在使用新的大量神经毒素之前，在转基因中对野生型小鼠进行初步实验。使用轻度至中度病变，可以观察转基因的影响:严重的病变可能会产生"地板效应"，伤害过于严重，无法衰减或破坏，从而掩盖有害基因改变的影响?...

Watch this Scientific Journal Video about Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease at JoVE.com

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

脂氧酶 （LOX） 异酶可以产生可能增加或减少神经发炎和神经退化的产品。基因-环境相互作用研究可以识别LOX异位素特异性效应。使用1-甲基-4-苯-1，2，3，6-四氢皮里丁（MPTP）模型的硝基丙烯损伤在两个LOX异酶缺乏转基因线允许比较LOX异位素对多巴胺完整性和炎症的贡献。

基因-环境相互作用模型揭开帕金森病的隐形易感机制

Lipoxygenase (LOX) activity has been implicated in neurodegenerative disorders such as Alzheimer&#39;s disease, but its effects in Parkinson&#39;s disease ...

gene-environment-interaction-models-to-unmask-susceptibility

Universidad de Cartagena UDEC

Research

JoVE Journal

Medicine

6.6K 次观看.  SRI International. 脂氧酶 （LOX） 异酶可以产生可能增加或减少神经发炎和神经退化的产品。基因-环境相互作用研究可以识别LOX异位素特异性效应。使用1-甲基-4-苯-1，2，3，6-四氢皮里丁（MPTP）模型的硝基丙烯损伤在两个LOX异酶缺乏转基因线允许比较LOX异位素对多巴胺完整性和炎症的贡献。

视频: Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Experimental Generation of Carcinoma-Associated Fibroblasts (CAFs) from Human Mammary Fibroblasts

Carcinomas are complex tissues comprised of neoplastic cells and a non-cancerous compartment referred to as the 'stroma'. The stroma consists of extracellular matrix (ECM) and a variety of mesenchymal cells, including fibroblasts, myofibroblasts, endothelial cells, pericytes and leukocytes 1-3.
The tumour-associated stroma is responsive to substantial paracrine signals released by neighbouring carcinoma cells. During the disease process, the stroma often becomes populated by carcinoma-associated fibroblasts (CAFs) including large numbers of myofibroblasts. These cells have previously been extracted from many different types of human carcinomas for their in vitro culture. A subpopulation of CAFs is distinguishable through their up-regulation of &alpha;-smooth muscle actin (&alpha;-SMA) expression4,5. These cells are a hallmark of 'activated fibroblasts' that share similar properties with myofibroblasts commonly observed in injured and fibrotic tissues 6. The presence of this myofibroblastic CAF subset is highly related to high-grade malignancies and associated with poor prognoses in patients.
Many laboratories, including our own, have shown that CAFs, when injected with carcinoma cells into immunodeficient mice, are capable of substantially promoting tumourigenesis 7-10. CAFs prepared from carcinoma patients, however, frequently undergo senescence during propagation in culture limiting the extensiveness of their use throughout ongoing experimentation. To overcome this difficulty, we developed a novel technique to experimentally generate immortalised human mammary CAF cell lines (exp-CAFs) from human mammary fibroblasts, using a coimplantation breast tumour xenograft model.
In order to generate exp-CAFs, parental human mammary fibroblasts, obtained from the reduction mammoplasty tissue, were first immortalised with hTERT, the catalytic subunit of the telomerase holoenzyme, and engineered to express GFP and a puromycin resistance gene. These cells were coimplanted with MCF-7 human breast carcinoma cells expressing an activated ras oncogene (MCF-7-ras cells) into a mouse xenograft. After a period of incubation in vivo, the initially injected human mammary fibroblasts were extracted from the tumour xenografts on the basis of their puromycin resistance 11.
We observed that the resident human mammary fibroblasts have differentiated, adopting a myofibroblastic phenotype and acquired tumour-promoting properties during the course of tumour progression. Importantly, these cells, defined as exp-CAFs, closely mimic the tumour-promoting myofibroblastic phenotype of CAFs isolated from breast carcinomas dissected from patients. Our tumour xenograft-derived exp-CAFs therefore provide an effective model to study the biology of CAFs in human breast carcinomas. The described protocol may also be extended for generating and characterising various CAF populations derived from other types of human carcinomas.

Experimental Generation of Carcinoma-Associated Fibroblasts CAFs from Human Mammary Fibroblasts

Carcinoma-associated fibroblasts (CAFs) rich in myofibroblasts present within the tumour stroma, play a major role in driving tumour progression. We developed a coimplantation tumour xengraft model for experimentally generating CAFs from human mammary fibroblasts. The protocol describes how to establish CAF myofibroblasts that acquire an ability to promote tumourigenesis.

从人类乳腺成纤维细胞癌相关的成纤维细胞的实验发电（CAFS）

Carcinomas are complex tissues comprised of neoplastic cells and a non-cancerous compartment referred to as the 'stroma'. The stroma consists of ...

科研

医学

Development of a Unilaterally-lesioned 6-OHDA Mouse Model of Parkinson's Disease

The unilaterally lesioned 6-hyroxydopamine (6-OHDA)-lesioned rat model of Parkinson's disease (PD) has proved to be invaluable in advancing our understanding of the mechanisms underlying parkinsonian symptoms, since it recapitulates the changes in basal ganglia circuitry and pharmacology observed in parkinsonian patients1-4. However, the precise cellular and molecular changes occurring at cortico-striatal synapses of the output pathways within the striatum, which is the major input region of the basal ganglia remain elusive, and this is believed to be site where pathological abnormalities underlying parkinsonian symptoms arise3,5.
In PD, understanding the mechanisms underlying changes in basal ganglia circuitry following degeneration of the nigro-striatal pathway has been greatly advanced by the development of bacterial artificial chromosome (BAC) mice over-expressing green fluorescent proteins driven by promoters specific for the two striatal output pathways (direct pathway: eGFP-D1; indirect pathway: eGFP-D2 and eGFP-A2a)8, allowing them to be studied in isolation. For example, recent studies have suggested that there are pathological changes in synaptic plasticity in parkinsonian mice9,10. However, these studies utilised juvenile mice and acute models of parkinsonism. It is unclear whether the changes described in adult rats with stable 6-OHDA lesions also occur in these models. Other groups have attempted to generate a stable unilaterally-lesioned 6-OHDA adult mouse model of PD by lesioning the medial forebrain bundle (MFB), unfortunately, the mortality rate in this study was extremely high, with only 14% surviving the surgery for 21 days or longer11. More recent studies have generated intra-nigral lesions with both a low mortality rate &gt;80% loss of dopaminergic neurons, however expression of L-DOPA induced dyskinesia11,12,13,14 was variable in these studies. Another well established mouse model of PD is the MPTP-lesioned mouse15. Whilst this model has proven useful in the assessment of potential neuroprotective agents16, it is less suitable for understanding mechanisms underlying symptoms of PD, as this model often fails to induce motor deficits, and shows a wide variability in the extent of lesion17, 18.
Here we have developed a stable unilateral 6-OHDA-lesioned mouse model of PD by direct administration of 6-OHDA into the MFB, which consistently causes &gt;95% loss of striatal dopamine (as measured by HPLC), as well as producing the behavioural imbalances observed in the well characterised unilateral 6-OHDA-lesioned rat model of PD. This newly developed mouse model of PD will prove a valuable tool in understanding the mechanisms underlying generation of parkinsonian symptoms.

A protocol for performing unilateral 6-OHDA lesions of the medial forebrain bundle in mice is described. This method has a low mortality rate (13.3 %) with 89% of the surviving animals showing &#62;95% loss of striatal dopamine and 90.63&#177;-4.02 % ipsiversive rotational bias towards the side of the lesion.

1单侧损毁6  - 羟基多巴胺帕金森病小鼠模型的发展

The unilaterally lesioned 6-hyroxydopamine (6-OHDA)-lesioned rat model of Parkinson's disease (PD) has proved to be invaluable in advancing our ...

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease

MALDI imaging mass spectrometry (IMS) is a powerful approach that facilitates the spatial analysis of molecular species in biological tissue samples2 (Fig.1). A 12 &mu;m thin tissue section is covered with a MALDI matrix, which facilitates desorption and ionization of intact peptides and proteins that can be detected with a mass analyzer, typically using a MALDI TOF/TOF mass spectrometer. Generally hundreds of peaks can be assessed in a single rat brain tissue section. In contrast to commonly used imaging techniques, this approach does not require prior knowledge of the molecules of interest and allows for unsupervised and comprehensive analysis of multiple molecular species while maintaining high molecular specificity and sensitivity2. Here we describe a MALDI IMS based approach for elucidating region-specific distribution profiles of neuropeptides in the rat brain of an animal model Parkinson's disease (PD). 
PD is a common neurodegenerative disease with a prevalence of 1% for people over 65 of age3,4. The most common symptomatic treatment is based on dopamine replacement using L-DOPA5. However this is accompanied by severe side effects including involuntary abnormal movements, termed L-DOPA-induced dyskinesias (LID)1,3,6. One of the most prominent molecular change in LID is an upregulation of the opioid precursor prodynorphin mRNA7. The dynorphin peptides modulate neurotransmission in brain areas that are essentially involved in movement control7,8. However, to date the exact opioid peptides that originate from processing of the neuropeptide precursor have not been characterized. Therefore, we utilized MALDI IMS in an animal model of experimental Parkinson's disease and L-DOPA induced dyskinesia. 
MALDI imaging mass spectrometry proved to be particularly advantageous with respect to neuropeptide characterization, since commonly used antibody based approaches targets known peptide sequences and previously observed post-translational modifications. By contrast MALDI IMS can unravel novel peptide processing products and thus reveal new molecular mechanisms of neuropeptide modulation of neuronal transmission. While the absolute amount of neuropeptides cannot be determined by MALDI IMS, the relative abundance of peptide ions can be delineated from the mass spectra, giving insights about changing levels in health and disease. In the examples presented here, the peak intensities of dynorphin B, alpha-neoendorphin and substance P were found to be significantly increased in the dorsolateral, but not the dorsomedial, striatum of animals with severe dyskinesia involving facial, trunk and orolingual muscles (Fig. 5). Furthermore, MALDI IMS revealed a correlation between dyskinesia severity and levels of des-tyrosine alpha-neoendorphin, representing a previously unknown mechanism of functional inactivation of dynorphins in the striatum as the removal of N-terminal tyrosine reduces the dynorphin's opioid-receptor binding capacity9. This is the first study on neuropeptide characterization in LID using MALDI IMS and the results highlight the potential of the technique for application in all fields of biomedical research.

Dopamine replacement pharmacotherapy using L-DOPA is the most commonly used symptomatic treatment of Parkinson&#x2019;s disease, but is accompanied by side effects including involuntary abnormal movements, termed dyskinesia 1. Here, a protocol for MALDI imaging mass spectrometry is presented that detects changes in rat brain neuropeptide levels related to dyskinesia.

MALDI成像帕金森病的神经肽质谱

MALDI imaging mass spectrometry (IMS) is a powerful approach that facilitates the spatial analysis of molecular species in biological tissue samples2 ...

Skin Punch Biopsy Explant Culture for Derivation of Primary Human Fibroblasts

Tissues and cell lines derived from an individual with disease are ideal sources to study disease-related cellular phenotypes. Patient-derived fibroblasts in this protocol have been successfully used in the derivation of induced pluripotent stem cells to model disease1. Early passages of these fibroblasts can also be used for cell-based functional assays to study specific disease pathways, mechanisms2 and subsequent drug screening approaches. The advantage of the presented protocol over enzymatic procedures are 1) the reproducibility of the technique from small amounts of tissue derived from older patients, e.g. patients affected with Parkinson's disease, 2) the technically simple approach over more challenging methodologies using enzymatic treatments, and 3) the time consideration: this protocol takes 15-20 min and can be performed immediately after biopsy arrival. Enzymatic treatments can take up to 4 hr and have the problems of overdigestion, reduction of cell viability and subsequent attachment of cells when not handled properly. This protocol describes the dissection and preparation of a 4-mm human skin biopsy for derivation of a fibroblast culture and has a very high success rate which is important when dealing with patient-derived tissue samples. In this culture, keratinocytes migrate out of the biopsy tissue within the first week after preparation. Fibroblasts appear 7-10 days after the first outgrowth of keratinocytes. DMEM high glucose media supplemented with 20% FBS favors the growth of fibroblasts over keratinocytes and fibroblasts will overgrow the keratinocytes. After 2 passages keratinocytes have been diluted out resulting in relatively homogenous fibroblast cultures which expresses the fibroblast marker SERPINH1 (HSP-47). Using this approach, 15-20 million fibroblasts can be derived in 4-8 weeks for cell banking. The skin dissection takes about 15-20 min, cells are then monitored once a day under the microscope, and media is changed every 2-3 days after attachment and outgrowth of cells.

The fibroblast explant culture protocol from human skin punch biopsies is a technically robust and simple way to derive skin cells within 4-8 weeks for banking of about 15-20 million cells at a low passage number.

推导人类纤维原细胞的皮肤穿刺活检植文化

Tissues and cell lines derived from an individual with disease are ideal sources to study disease-related cellular phenotypes. Patient-derived fibroblasts ...

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Parkinson's disease (PD) is the second most common movement disorder and affects 1% of people over the age of 60 1. Because ageing is the most important risk factor, cases of PD will increase during the next decades 2. Next to pathological protein folding and impaired protein degradation pathways, alterations of mitochondrial function and morphology were pointed out as further hallmark of neurodegeneration in PD 3-11.
After years of research in murine and human cancer cells as in vitro models to dissect molecular pathways of Parkinsonism, the use of human fibroblasts from patients and appropriate controls as ex vivo models has become a valuable research tool, if potential caveats are considered. Other than immortalized, rather artificial cell models, primary fibroblasts from patients carrying disease-associated mutations apparently reflect important pathological features of the human disease.
Here we delineate the procedure of taking skin biopsies, culturing human fibroblasts and using detailed protocols for essential microscopic techniques to define mitochondrial phenotypes. These were used to investigate different features associated with PD that are relevant to mitochondrial function and dynamics. Ex vivo, mitochondria can be analyzed in terms of their function, morphology, colocalization with lysosomes (the organelles degrading dysfunctional mitochondria) and degradation via the lysosomal pathway. These phenotypes are highly relevant for the identification of early signs of PD and may precede clinical motor symptoms in human disease-gene carriers. Hence, the assays presented here can be utilized as valuable tools to identify pathological features of neurodegeneration and help to define new therapeutic strategies in PD.

Fibroblasts from patients carrying mutations in Parkinson's disease-causing genes represent an easily accessible ex vivo model to study disease-associated phenotypes. Live cell imaging gives the opportunity to study morphological and functional parameters in living cells. Here we describe the preparation of human fibroblasts and subsequent monitoring of mitochondrial phenotypes.

利用人类纤维原细胞线粒体表型的监测领域的帕金森氏病

Parkinson's disease (PD) is the second most  common movement disorder and affects 1% of people over the age of 60 1. Because ageing is  the most important ...

Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation

Adaptive deep brain stimulation (aDBS) has the potential to improve the treatment of Parkinson&#39;s disease by optimizing stimulation in real time according to fluctuating disease and medication state. In the present realization of adaptive DBS we record and stimulate from the DBS electrodes implanted in the subthalamic nucleus of patients with Parkinson&#39;s disease in the early post-operative period. Local field potentials are analogue filtered between 3 and 47 Hz before being passed to a data acquisition unit where they are digitally filtered again around the patient specific beta peak, rectified and smoothed to give an online reading of the beta amplitude. A threshold for beta amplitude is set heuristically, which, if crossed, passes a trigger signal to the stimulator. The stimulator then ramps up stimulation to a pre-determined clinically effective voltage over 250 msec and continues to stimulate until the beta amplitude again falls down below threshold. Stimulation continues in this manner with brief episodes of ramped DBS during periods of heightened beta power.
Clinical efficacy is assessed after a minimum period of stabilization (5 min) through the unblinded and blinded video assessment of motor function using a selection of scores from the Unified Parkinson&#39;s Rating Scale (UPDRS). Recent work has demonstrated a reduction in power consumption with aDBS as well as an improvement in clinical scores compared to conventional DBS. Chronic aDBS could now be trialed in Parkinsonism.

Adaptive deep brain stimulation (aDBS) is effective for Parkinson&#8217;s disease, improving symptoms and reducing power consumption compared to conventional deep brain stimulation (cDBS). In aDBS we track a local field potential biomarker (beta oscillatory amplitude) in real time and use this to control the timing of stimulation.

控制帕金森氏症与自适应深部脑刺激

Adaptive deep brain stimulation (aDBS) has the potential to improve the treatment of Parkinson&#39;s disease by optimizing stimulation in real time ...

Adapting Human Videofluoroscopic Swallow Study Methods to Detect and Characterize Dysphagia in Murine Disease Models

This study adapted human videofluoroscopic swallowing study (VFSS) methods for use with murine disease models for the purpose of facilitating translational dysphagia research. Successful outcomes are dependent upon three critical components: test chambers that permit self-feeding while standing unrestrained in a confined space, recipes that mask the aversive taste/odor of commercially-available oral contrast agents, and a step-by-step test protocol that permits quantification of swallow physiology. Elimination of one or more of these components will have a detrimental impact on the study results. Moreover, the energy level capability of the fluoroscopy system will determine which swallow parameters can be investigated. Most research centers have high energy fluoroscopes designed for use with people and larger animals, which results in exceptionally poor image quality when testing mice and other small rodents. Despite this limitation, we have identified seven VFSS parameters that are consistently quantifiable in mice when using a high energy fluoroscope in combination with the new murine VFSS protocol. We recently obtained a low energy fluoroscopy system with exceptionally high imaging resolution and magnification capabilities that was designed for use with mice and other small rodents. Preliminary work using this new system, in combination with the new murine VFSS protocol, has identified 13 swallow parameters that are consistently quantifiable in mice, which is nearly double the number obtained using conventional (i.e., high energy) fluoroscopes. Identification of additional swallow parameters is expected as we optimize the capabilities of this new system. Results thus far demonstrate the utility of using a low energy fluoroscopy system to detect and quantify subtle changes in swallow physiology that may otherwise be overlooked when using high energy fluoroscopes to investigate murine disease models.

This study successfully adapted human videofluoroscopic swallowing study (VFSS) methods for use with murine disease models for the purpose of facilitating translational dysphagia research.

适应人类Videofluoroscopic燕子研究的方法来检测和检定吞咽困难的小鼠疾病模型

This study adapted human videofluoroscopic swallowing study (VFSS) methods for use with murine disease models for the purpose of facilitating ...

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease

The epithelial barrier is the first innate defense of the gastrointestinal tract and selectively regulates transport from the lumen to the underlying tissue compartments, restricting the transport of smaller molecules across the epithelium and almost completely prohibiting epithelial macromolecular transport. This selectivity is determined by the mucous gel layer, which limits the transport of lipophilic molecules and both the apical receptors and tight junctional protein complexes of the epithelium. In vitro cell culture models of the epithelium are convenient, but as a model, they lack the complexity of interactions between the microbiota, mucous-gel, epithelium and immune system. On the other hand, in vivo assessment of intestinal absorption or permeability may be performed, but these assays measure overall gastrointestinal absorption, with no indication of site specificity. Ex vivo permeability assays using &#34;intestinal sacs&#34; are a rapid and sensitive method of measuring either overall intestinal integrity or comparative transport of a specific molecule, with the added advantage of intestinal site specificity. Here we describe the preparation of intestinal sacs for permeability studies and the calculation of the apparent permeability (Papp) of a molecule across the intestinal barrier. This technique may be used as a method of assessing drug absorption, or to examine regional epithelial barrier dysfunction in animal models of gastrointestinal disease.

Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease

This protocol describes the use of excised intestinal tissue preparations or "intestinal sacs" as an ex vivo model of intestinal barrier function. This model may be used to assess integrity of both the epithelial barrier and the mucous gel layer at specific intestinal sites in animal models of digestive disease.

体外肠囊评估黏膜通透性在胃肠道疾病模型

The epithelial barrier is the first innate defense of the gastrointestinal tract and selectively regulates transport from the lumen to the underlying ...

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

Neuroinflammation is now recognized as a major etiological factor in neurodegenerative disease. Mononuclear phagocytes are innate immune cells responsible for phagocytosis and clearance of debris and detritus. These cells include CNS-resident macrophages known as microglia, and mononuclear phagocytes infiltrating from the periphery. Light microscopy has generally been used to visualize phagocytosis in rodent or human brain specimens. However, qualitative methods have not provided definitive evidence of in vivo phagocytosis. Here, we describe quantitative 3D in silico modeling (q3DISM), a robust method allowing for true 3D quantitation of amyloid-&#946; (A&#946;) phagocytosis by mononuclear phagocytes in rodent Alzheimer&#39;s Disease (AD) models. The method involves fluorescently visualizing A&#946; encapsulated within phagolysosomes in rodent brain sections. Large z-dimensional confocal datasets are then 3D reconstructed for quantitation of A&#946; spatially colocalized within the phagolysosome. We demonstrate the successful application of q3DISM to mouse and rat brains, but this methodology can be extended to virtually any phagocytic event in any tissue.

Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease

We developed a methodology for quantitative 3D in silico modeling (q3DISM) of cerebral amyloid-&#946; (A&#946;) phagocytosis by mononuclear phagocytes in rodent models of Alzheimer&#39;s disease. This method can be generalized for the quantitation of virtually any phagocytic event in vivo.

定量3D<em&gt;在硅片</em&gt;建模阿尔茨海默病的啮齿动物模型脑淀粉样蛋白-β吞噬（q3DISM）

Neuroinflammation is now recognized as a major etiological factor in neurodegenerative disease. Mononuclear phagocytes are innate immune cells responsible ...

Repeated Measurement of Respiratory Muscle Activity and Ventilation in Mouse Models of Neuromuscular Disease

Accessory respiratory muscles help to maintain ventilation when diaphragm function is impaired. The following protocol describes a method for repeated measurements over weeks or months of accessory respiratory muscle activity while simultaneously measuring ventilation in a non-anesthetized, freely behaving mouse. The technique includes the surgical implantation of a radio transmitter and the insertion of electrode leads into the scalene and trapezius muscles to measure the electromyogram activity of these inspiratory muscles. Ventilation is measured by whole-body plethysmography, and animal movement is assessed by video and is synchronized with electromyogram activity. Measurements of muscle activity and ventilation in a mouse model of amyotrophic lateral sclerosis are presented to show how this tool can be used to investigate how respiratory muscle activity changes over time and to assess the impact of muscle activity on ventilation. The described methods can easily be adapted to measure the activity of other muscles or to assess accessory respiratory muscle activity in additional mouse models of disease or injury.

This paper introduces a method for repeated measurements of ventilation and respiratory muscle activity in a freely behaving amyotrophic lateral sclerosis (ALS) mouse model throughout disease progression with whole-body plethysmography and electromyography via an implanted telemetry device.

在神经肌肉疾病的模型小鼠呼吸肌肉活动和通风的重复测量

Accessory respiratory muscles help to maintain ventilation when diaphragm function is impaired. The following protocol describes a method for repeated ...

基因-环境相互作用模型揭开帕金森病的隐形易感机制

摘要

探索更多视频

此视频中的章节